Merck的药物 WINREVIR在一次与心脏衰竭有关的罕见肺病试验中达到了它的目标,显示出对重大未满足需求的希望。 Merck's drug WINREVAIR met its goal in a trial for a rare lung condition linked to heart failure, showing promise for a major unmet need.

默克公司宣布,其对WINREVAIR (sotatercept- csrk) 的2期CADENCE试验达到了主要终点,显示肺血管抵抗在因心力衰竭而导致肺高血压后和前毛细血管高血压 (HFpEF) 综合的成年人显著降低. Merck announced that its Phase 2 CADENCE trial of WINREVAIR (sotatercept-csrk) met its primary endpoint, showing a significant reduction in pulmonary vascular resistance in adults with combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction (HFpEF). 该药物展示了与先前数据一致的有利安全特征,Merck计划将其推进到第三阶段试验。 The drug demonstrated a favorable safety profile consistent with prior data, and Merck plans to advance it into Phase 3 trials. 这些结果于2025年11月18日公布,标志着在治疗一种罕见、复杂的肺高血压形式方面取得了进展,但选择有限。 The results, released on November 18, 2025, mark progress in treating a rare, complex form of pulmonary hypertension with limited options. 默克的股价在新闻上了3%以上,反映了对药物在HFpEF的潜力充满乐观, 这种情况影响了超过670万美国人. Merck’s stock rose over 3% on the news, reflecting optimism about the drug’s potential in HFpEF, a condition affecting over 6.7 million Americans. WINREVAIR已经获准用于肺动脉高血压,到2025年9月销售额为9.76亿美元。 WINREVAIR is already approved for pulmonary arterial hypertension and generated $976 million in sales through September 2025.